Pathways to Ending Federal Prohibition: An Overview of Descheduling & Rescheduling. In 2022, President Biden directed his administration to conduct a review of the status of cannabis under the Controlled Substances Act. This session examines the review process for descheduling and rescheduling and their potential impacts.
This program is eligible for 1 hours of General CLE credit in 60-minute states, and 1.2 hours of General CLE credit in 50-minute states. Credit hours are estimated and are subject to each state’s approval and credit rounding rules.
INCBA webinars are generally eligible for credit in the following states: AR, AL, CA, CO, GA, HI, IL, NJ, NM, NY, ND, PA, TX, VT. Additional states may be available for credit upon self-application by attendees. States typically decide whether a program qualifies for MCLE credit in their jurisdiction 4-8 weeks after the program application is submitted. For many live events, credit approval is not received prior to the program.
The on-demand version of this webinar is eligible for credit in the following states: AR, AL, CA, CO, GA, HI, IL, NJ, NM, NY, ND, PA, TX, VT. Additional states may be available for credit upon self-application by attendees.
(Default credit disclaimer updated 02.08.2024)
For current accreditation status, please select your jurisdiction below.
DEA. 10 July, 2018. Drug Scheduling.pdf
(264.7 KB)
DEA. 10 July, 2018. Drug Scheduling.pdf |
Available after Purchase |
Drugs of Abuse - A DEA Resource Guide (2020 Edition).pdf
(7.1 MB)
Drugs of Abuse - A DEA Resource Guide (2020 Edition).pdf |
Available after Purchase |
FDA and Cannabis_ Research and Drug Approval Process _ FDA.pdf
(349.6 KB)
FDA and Cannabis_ Research and Drug Approval Process _ FDA.pdf |
Available after Purchase |
FDA Role in Regulation of Cannabis Products PowerPoint Presentation.pdf
(320.6 KB)
FDA Role in Regulation of Cannabis Products PowerPoint Presentation.pdf |
Available after Purchase |
INCBA CLE Pathways to Ending Federal Prohibition Outline.pdf
(210.1 KB)
INCBA CLE Pathways to Ending Federal Prohibition Outline.pdf |
Available after Purchase |
marijuana scheduling resources.docx
(13.2 KB)
marijuana scheduling resources.docx |
Available after Purchase |
Pathways to Ending Federal Prohibition An Overview of Descheduling & Rescheduling.pptx
(2.5 MB)
Pathways to Ending Federal Prohibition An Overview of Descheduling & Rescheduling.pptx |
Available after Purchase |
Pathways to Ending Federal Prohibition_ An Overview of Descheduling & Rescheduling_REFERENCE LINKS.pdf
(67 KB)
Pathways to Ending Federal Prohibition_ An Overview of Descheduling & Rescheduling_REFERENCE LINKS.pdf |
Available after Purchase |
Recommendation to Maintain Marijuana in Schedule I of the Controlled Substances Act.pdf
(57.3 MB)
Recommendation to Maintain Marijuana in Schedule I of the Controlled Substances Act.pdf |
Available after Purchase |
Statement from President Biden on Marijuana Reform _ The White House.pdf
(32.1 KB)
Statement from President Biden on Marijuana Reform _ The White House.pdf |
Available after Purchase |
The Controlled Substances Act.pdf
(260.5 KB)
The Controlled Substances Act.pdf |
Available after Purchase |
The Schedule I Status of Marijuana.pdf
(757.7 KB)
The Schedule I Status of Marijuana.pdf |
Available after Purchase |
Steph Sherer is the foremost international leader and expert on medical cannabis patient advocacy. In 2002, Sherer founded Americans for Safe Access (ASA), the largest national member-based organization of patients, medical professionals, scientists, and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. For seventeen years, Sherer's leadership guided the efforts, with lawmakers across the country, to adopt and improve medical cannabis legislation and regulatory policy across the US and its territories as well as representing patients on Capitol Hill. Sherer remains President of ASA and has expanded her focus to strengthen the industry. Alongside the American Herbal Products Association (AHPA) and the American Herbal Pharmacia, Sherer co-created the first medical cannabis industry standards in the areas of Distribution, Cultivation, Analytics, and Manufacturing, Packaging, and Labeling. She is also a founding member of the International Medical Cannabis Patients Coalition (IMCPC), a patient advocacy organization committed to fighting for access to critically needed medicine.
Jessica Wasserman is the founder and CEO of WassermanRowe, a DC-based law and government relations firm providing services to Food and Drug Administration-regulated industries, including food, supplements, medical devices, botanical drugs and drugs. She has worked in Congress, federal agencies (at both career and political levels) and major law firms. She has worked on hemp and cannabinoid issues since the 2018 Farm Bill decriminalized and defined hemp. Having worked at the U.S. Department of Agriculture, she hit the ground running on the hemp harvest issues and then pivoted to the cannabis FDA issues (Warning Letters for drug label claims compliance; GMPs; Epidiolex drug preclusion issue; GRAS; NDI) as CBD manufacturers and retailers faced these issues. Currently, Jessica lobbies and advises on compliance on a wide range of cannabis issues, including reauthorization of the 2018 Farm Bill; the proliferation of state laws focused on “intoxicating” cannabinoid products; compliance for edible products sold in dispensaries; federal lobbying on the ongoing FDA cannabis scheduling review and more. Jessica is a graduate of the University of Michigan Law School.
Seema is an attorney and seasoned campaign strategist. Seema was Senior Policy Advisor - Racial Equity, Criminal Justice and Policing for the Biden for President campaign. Prior to that, Seema served as Managing Director of Government Affairs and State Campaigns for the Alliance for Safety and Justice.
Seema is an experienced documentary filmmaker and campaign strategist for social movements in the United States and abroad. She is a graduate of American University’s Washington College of Law and Tulane University and currently resides in Washington, D.C.
The United Empowerment Party works on the federal and with state level to provide policy guidance and to advocate for to fair and equitable legislation. UEP works with candidates on either side of the poitical ailse who are committed embracing diverse ideas and inclusive solutions to improve and expand the cannabis industry through health care research and innovative product development.
5 |
|
4 |
|
3 |
|
2 |
|
1 |
|